Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 6,400 shares, a drop of 12.3% from the February 28th total of 7,300 shares. Based on an average trading volume of 81,100 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Enzon Pharmaceuticals Trading Up 6.7 %

Shares of OTCMKTS:ENZN opened at $0.11 on Wednesday. The company has a 50-day moving average price of $0.12 and a 200-day moving average price of $0.12. The company has a market cap of $8.15 million, a price-to-earnings ratio of 10.99 and a beta of 0.26. Enzon Pharmaceuticals has a 12 month low of $0.06 and a 12 month high of $0.24.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.